

## Pubblicazioni ultimi 5 anni / Last 5 years publications

1. Scotch AH, Kosiorek H, Scherber R, et al. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. *Leuk Res.* 2017 Oct 14;63:34-40. doi: 10.1016/j.leukres.2017.10.002.
2. Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. *J Hematol Oncol.* 2017 Sep 29;10(1):156. doi: 10.1186/s13045-017-0527-7.
3. Vannucchi AM, Guglielmelli P. Traffic lights for ruxolitinib. *Blood.* 2017 Aug 31;130(9):1075-1077. doi: 10.1182/blood-2017-07-795880.
4. Ellis MH, Koren-Michowitz M, Lavi N, et al. Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. *Leuk Res.* 2017 Oct;61:6-9. doi: 10.1016/j.leukres.2017.08.002. Epub 2017 Aug 10.
5. Verstovsek S, Passamonti F, Rambaldi A, et al. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. *Blood.* 2017 Oct 12;130(15):1768-1771. doi: 10.1182/blood-2017-02-765032.
6. Tefferi A, Betti S, Barraco D, et al. Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. *Am J Hematol.* 2017 Nov;92(11):1193-1197. doi: 10.1002/ajh.24882.
7. Tefferi A, Vannucchi AM. Genetic Risk Assessment in Myeloproliferative Neoplasms. *Mayo Clin Proc.* 2017 Aug;92(8):1283-1290. doi: 10.1016/j.mayocp.2017.06.002. Review.
8. Ruberti S, Bianchi E, Guglielmelli P, et al. Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. *Leukemia.* 2017 Jul 12. doi: 10.1038/leu.2017.220.
9. Erba BG, Gruppi C, Corada M, et al. Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis. *Am J Pathol.* 2017 Aug;187(8):1879-1892. doi: 10.1016/j.ajpath.2017.04.006.
10. Barbui T, Vannucchi AM, Finazzi G, et al. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. *Am J Hematol.* 2017 Nov;92(11):1131-1136. doi: 10.1002/ajh.24851.
11. Kvasnicka HM, Orazi A, Thiele J, et al. European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. *Am J Hematol.* 2017 Oct;92(10):1062-1067. doi: 10.1002/ajh.24837.
12. Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. *Lancet Haematol.* 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1.
13. Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. *Leukemia.* 2017 May 31. doi: 10.1038/leu.2017.169.
14. Pacilli A, Fanelli T, Mannarelli C, et al. Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib. *Hematol Oncol.* 2017 May 5. doi: 10.1002/hon.2424
15. Tefferi A, Al-Ali HK, Barosi G, et al. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. *Leukemia.* 2017 May;31(5):1252. doi: 10.1038/leu.2017.2. No abstract available.

16. Guglielmelli P, Pietra D, Pane F, et al. Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology. *Leuk Res.* 2017 Jul;58:63-72. doi: 10.1016/j.leukres.2017.04.006. Epub 2017 Apr 23. Review.
17. Coltro G, Mannelli F, Guglielmelli P, et al. A life-threatening ruxolitinib discontinuation syndrome. *Am J Hematol.* 2017 Aug;92(8):833-838. doi: 10.1002/ajh.24775.
18. Vannucchi AM, Verstovsek S, Guglielmelli P, et al. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. *Ann Hematol.* 2017 Jul;96(7):1113-1120. doi: 10.1007/s00277-017-2994-x.
19. Rontautoli S, Norfo R, Pennucci V, et al. miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. *Oncotarget.* 2017 Mar 28;8(13):21380-21397. doi: 10.18632/oncotarget.15226.
20. Loscocco GG, Vannucchi M, Paoli C, et al. Kaposi sarcoma in a patient treated with ruxolitinib. *Ann Oncol.* 2017 Jul 1;28(7):1670-1671. doi: 10.1093/annonc/mdx188.
21. Goel S, Paoli C, Iurlo A, et al. Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. *Eur J Haematol.* 2017 Jul;99(1):36-41. doi: 10.1111/ejh.12887.
22. Guglielmelli P, Pacilli A, Rotunno G, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. *Blood.* 2017 Jun 15;129(24):3227-3236. doi: 10.1182/blood-2017-01-761999.
23. Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. *Lancet Haematol.* 2017 May;4(5):e225-e236. doi: 10.1016/S2352-3026(17)30027-3.
24. Barbui T, Carobbio A, Ghirardi A, et al. No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials. *Haematologica.* 2017 Jun;102(6):e219-e221. doi: 10.3324/haematol.2017.165126
25. Harrison CN, Vannucchi AM, Kiladjan JJ et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. *Leukemia.* 2017 Mar;31(3):775. doi: 10.1038/leu.2016.323.
26. Lussana F, Carobbio A, Salmoiraghi S, et al. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. *J Hematol Oncol.* 2017 Feb 22;10(1):54. doi: 10.1186/s13045-017-0425-z.
27. Barbui T, Thiele J, Gisslinger H, et al. Diagnostic impact of the 2016 revised who criteria for polycythemia vera. *Am J Hematol.* 2017 May;92(5):417-419. doi: 10.1002/ajh.24684.
28. Verstovsek S, Harrison CN, Kiladjan JJ, et al. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. *Leuk Res.* 2017 May;56:52-59. doi: 10.1016/j.leukres.2017.01.032.
29. Bianchi E, Ruberti S, Rontautoli S, et al. Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis. *Int J Mol Sci.* 2017 Jan 13;18(1). pii: E145. doi: 10.3390/ijms18010145.
30. Vannucchi AM, Harrison CN. Emerging treatments for classical myeloproliferative neoplasms. *Blood.* 2017 Feb 9;129(6):693-703. doi: 10.1182/blood-2016-10-695965. Epub 2016 Dec 27. Review.

31. Cervantes F, Vannucchi AM, Kiladjan J-J, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. *Blood*. 2013;122(25):4047-4053.
32. Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. *Lancet Oncol*. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7.
33. Passamonti F, Mora B, Giorgino T, et al. Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients. *Leukemia*. 2017 Apr;31(4):970-973. doi: 10.1038/leu.2016.351.
34. Vannucchi AM. From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. *Haematologica*. 2017 Jan;102(1):18-29. doi: 10.3324/haematol.2015.129155.
35. Pieri L, Paoli C, Arena U, et al. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. *Am J Hematol*. 2017 Feb;92(2):187-195. doi: 10.1002/ajh.24614.
36. Mesa R, Vannucchi AM, Yacoub A, et al. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). *Br J Haematol*. 2017 Jan;176(1):76-85. doi: 10.1111/bjh.14382.
37. Scherber RM, Geyer HL, Dueck AC, et al. The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. *Leuk Lymphoma*. 2017 Jun;58(6):1481-1487. doi: 10.1080/10428194.2016.1246733.
38. De Stefano V, Vannucchi AM, Ruggeri M, et al. Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. *Blood Cancer J*. 2016 Nov 4;6(11):e493. doi: 10.1038/bcj.2016.103.
39. Tefferi A, Al-Ali HK, Barosi G, et al. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. *Leukemia*. 2017 Apr;31(4):896-902. doi: 10.1038/leu.2016.300.
40. Marchetti M, Barosi G, Cervantes F, et al. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. *Leukemia*. 2017 Apr;31(4):882-888. doi: 10.1038/leu.2016.283.
41. Barbui T, Vannucchi AM, Carobbio A, et al. The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. *Am J Hematol*. 2017 Jan;92(1):E5-E6. doi: 10.1002/ajh.24583.
42. Koren-Michowitz M, Lavi N, Ellis MH, et al. Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey. *Ann Hematol*. 2017 Jan;96(1):87-92. doi: 10.1007/s00277-016-2826-4.
43. Geyer HL, Kosiorek H, Dueck AC, Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. *Haematologica*. 2017 Jan;102(1):85-93. doi: 10.3324/haematol.2016.149559. Epub 2016 Aug 18.
44. Koschmieder S, Mughal TI, Hasselbalch HC, et al. Myeloproliferative neoplasms and inflammation: Whether to target the malignant clone or the inflammatory process or both.

45. Rotunno G, Pacilli A, Artusi V, et al. Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group. *American Journal of Hematology*. 2016:n/a-n/a.
46. De Luca F, Rotunno G, Salvianti F, et al. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer.
47. Balliu M, Cellai C, Lulli M, et al. HDAC1 controls CIP2A transcription in human colorectal cancer cells.
48. Pieri L, Bonadonna P, Elena C, et al. Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. *American Journal of Hematology*. 2016:n/a-n/a.
49. Geyer HL, Andreasson B, Kosiorek HE, et al. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
50. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Myeloproliferative neoplasms: Morphology and clinical practice. *American Journal of Hematology*. 2016;91(4):430-433.
51. Gugliotta L, Iurlo A, Gugliotta G, et al. Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. *Leukemia Research*. 2016;46:18-25.
52. Verstovsek S, Vannucchi AM, Griesshammer M, et al. Ruxolitinib versus best available therapy in patients with Polycythemia Vera: 80 Week follow up from the RESPONSE trial.
53. Alvarez-Larran A, Pereira A, Guglielmelli P, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with CALR mutation.
54. De Stefano V, Ruggeri M, Cervantes F, et al. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists.
55. Calistri L, Pieri L, Santi R, Nardi C, Maria Vannucchi A, Colagrande S. MR imaging in non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis. *American Journal of Hematology*. 2016;91(10):1062-1063.
56. Loscocco GG, Mannarelli C, Pacilli A, et al. Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms. *Am J Hematol*. 2016.
57. Al-Ali HK, Griesshammer M, le Coutre P, et al. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
58. Guglielmelli P, Rotunno G, Pacilli A, et al. Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis. A Study of the AGIMM Group on 490 Patients. *American Journal of Hematology*. 2016;91(9):918-922.
59. Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Tefferi A. The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. *Blood Reviews*. 2016.
60. Calura E, Pizzini S, Bisognin A, et al. A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells. *Blood Cancer Journal*. 2016;6:e439
61. Geyer HL, Kosiorek H, Dueck AC, et al. Associations between gender, disease features and symptom burden in the MPN population: An analysis by the MPN QOL International Working Group.

62. Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.
63. Al-Ali HK, Vannucchi AM. Managing patients with myelofibrosis and low platelet counts. *Annals of Hematology*. 2016;1-12.
64. Pieri L, Vannucchi AM. Improving prognostic tools in systemic mastocytosis: Insights from mutations. *American Journal of Hematology*. 2016;91(9):867-868.
65. Shimizu T, Kubovcakova L, Nienhold R, et al. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. *The Journal of Experimental Medicine*. 2016.
66. Pieri L, Guglielmelli P, Vannucchi AM. Ruxolitinib-Induced Reversal of Alopecia Universalis in a Patient with Essential Thrombocythemia. *American Journal of Hematology*. 2015;90(1):82-83.
67. Barosi G, Tefferi A, Besses C, et al. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).
68. Vannucchi AM, Kiladjian JJ, Grieshammer M, et al. Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. *New England Journal of Medicine*. 2015;372(5):426-435.
69. Rago A, Latagliata R, Montanaro M, et al. Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. *Leuk Res*. 2015;39:314-317.
70. Ortmann CA, Kent DG, Nangalia J, et al. Effect of Mutation Order on Myeloproliferative Neoplasms. *New England Journal of Medicine*. 2015;372(7):601-612.
71. Barbui T, Vannucchi AM, Carobbio A, et al. Patterns of presentation and thrombosis outcome in patients with Polycythemia Vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. *American Journal of Hematology*. 2015;90(5):934-937.
72. Desterke C, Martinaud C, Guerton B, et al. The tetraspanin CD9 participates in dysmegakaryopoiesis and in stroma interactions in primary myelofibrosis.
73. Kroger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis.
74. Pardanani A, Tefferi A, Guglielmelli P, et al. Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial. *Blood Cancer J*. 2015;5:e286.
75. Passamonti F, Vannucchi AM, Cervantes F, et al. Ruxolitinib and survival improvement in patients with myelofibrosis.
76. Pennucci V, Zini R, Norfo R, et al. Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. *Leuk Lymphoma*. 2015;56(2):492-496.
77. Tapper W, Jones AV, Kralovics R, et al. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. *Nat Commun*. 2015;6:6691.
78. Vannucchi AM. Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. *New England Journal of Medicine*. 2015;372(17):1670-1671.
79. Barbui T, Thiele J, Carobbio A, Vannucchi AM, Tefferi A. The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis.

80. Pieri L, Pancrazzi A, Pacilli A, et al. JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.
81. Vannucchi AM, Kantarjian HM, Kiladjian J-J, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis; 2015.
82. Emmi G, Silvestri E, Marconi R, et al. First report of FIP1L1-PDGFR $\alpha$ -positive eosinophilic granulomatosis with polyangiitis.
83. Cascavilla N, De Stefano V, Pane F, et al. Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. *Drug Des Devel Ther.* 2015;9:2687-2694.
84. Chase A, Leung W, Tapper W, et al. Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus.
85. Vannucchi AM. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. *N Engl J Med.* 2015;372(17):1670-1671.
86. Finazzi MC, Carobbio A, Cervantes F, et al. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.
87. Castelli R, Cugno M, Gianelli U, Pancrazzi A, Vannucchi AM. Neutrophilic progression in a case of polycythemia vera mimicking chronic neutrophilic leukemia: clinical and molecular characterization. *Pathol Res Pract.* 2015;211(4):341-343.
88. Pardanani A, Harrison C, Cortes JE, et al. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. *JAMA Oncol.* 2015.
89. Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study.
90. Vannucchi AM, Barbui T, Cervantes F, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up dagger. *Ann Oncol.* 2015.
91. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. *Blood Cancer Journal.* 2015;5:e337.
92. Alessandro MV, Niccolò B, Lisa P, Paola G. Rationale for combination therapies in myelofibrosis. *Novel Insights into Myelofibrosis Pathophysiology and Treatment: Future Medicine Ltd;* 2015:136-150.
93. Kroger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an ebmt/elb international working group.
94. Guglielmelli P, Rotunno G, Fanelli T, et al. Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. *Blood Cancer Journal.* 2015;2015:In Press.
95. Tenedini E, Bernardis I, Artusi V, et al. Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms.
96. Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.

97. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of Calreticulin Mutations on Clinical and Hematological Phenotype and Outcome in Essential Thrombocythemia.
98. Barosi G, Vannucchi AM, De Stefano V, et al. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper. *Leukemia research*. 2014;38(2):155-160.
99. Passamonti F, Maffioli M, Cervantes F, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.
100. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.
101. Guglielmelli P, Biamonte F, Rotunno G, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II Study.
102. Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia Vera (mPV): Results of an international study. *American Journal of Hematology*. 2014;89(1):52-54.
103. Guglielmelli P, Nangalia J, Green AR, Vannucchi AM. CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum. *American Journal of Hematology*. 2014;89(5):453-456.
104. Barbui T, Thiele J, Carobbio A, et al. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. *Am J Hematol*. 2014;89(6):588-590.
105. Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
106. Vannucchi AM, Rotunno G, Bartalucci N, et al. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value.
107. Tefferi A, Wassie EA, Guglielmelli P, et al. Type 1 vs Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. *Am J Hematol*. 2014;28::1568-1570.
108. Pennucci V, Zini R, Norfo R, et al. Abnormal Expression of WT1-as, MEG3 and ANRIL Long Non-Coding RNAs in CD34+ Cells from Patients with Primary Myelofibrosis and Its Clinical Correlations. *Leuk Lymphoma*. 2014;56(2):492-496.
109. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.
110. Storlazzi TC, Pieri L, Paoli C, et al. Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. *Am J Hematol*. 2014;89(4):438-442.
111. Randi ML, Bertozzi I, Rumi E, et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. *Am J Hematol*. 2014;89(3):306-309.
112. Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. *Am J Hematol*. 2014;89(2):199-202.
113. Mesa RA, Kiladjian JJ, Verstovsek S, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
114. Rotunno G, Guglielmelli P, Biamonte F, Rumi E, Cazzola M, Vannucchi AM. Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. *Ann Hematol*. 2014;93(3):523-524.
115. Mughal TI, Vannucchi AM, Soverini S, et al. Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.
116. Geyer HL, Emanuel RM, Dueck AC, et al. Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.

117. Ellis MH, Lavi N, Vannucchi A, Harrison C. Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: A physician survey. *Thromb Res.* 2014;134(2):251-254.
118. Guglielmelli P, Bartalucci N, Rotunno G, Vannucchi AM. Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms. *Expert Review of Hematology.* 2014;0(0):1-3.
119. Barbui T, Thiele J, Kvasnicka HM, Carobbio A, Vannucchi AM, Tefferi A. Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification.
120. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rethinking the diagnostic criteria of polycythemia vera.
121. Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR or MPL in primary myelofibrosis.
122. Rondelli D, Goldberg JD, Isola L, et al. MPD-RC 101 prospective study of reduced intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
123. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis.
124. Martinelli I, De Stefano V, Carobbio A, et al. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European leukemia Net study. *Am J Hematol.* 2014;89(11):E200-205.
125. Pieri L, Guglielmelli P, Finazzi G, Vannucchi AM. Givinostat for the treatment of polycythemia vera. *Expert Opinion on Orphan Drugs.* 2014;2(8):841-850.
126. Norfo R, Zini R, Pennucci V, et al. miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the role of miR-155/JARID2 axis in abnormal megakaryopoiesis.
127. Vannucchi AM. How I treat Polycythemia vera.
128. Lussana F, Carobbio A, Randi ML, et al. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. *British Journal of Haematology.* 2014;167(4):541-546.
129. Barbui T, Carobbio A, Rumi E, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.
130. Finazzi MC, Carobbio A, Cervantes F, et al. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in Primary Myelofibrosis.
131. Finazzi G, Carobbio A, Guglielmelli P, et al. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.
132. Durrant S, Koren-Michowitz M, Lavie D, et al. HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF).
133. Gupta V, Koschmieder S, Harrison CN, et al. Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis.
134. Kiladjan J-J, Heidel FH, Vannucchi AM, et al. Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis.



135. Verstovsek S, Passamonti F, Rambaldi A, et al. Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea.
136. Vannucchi AM. Prognosis of essential thrombocythemia and polycythemia vera. In: Mesa K, Harrison, Verstovsek, Vannucchi eds., ed. Myeloproliferative Neoplasms: Clinician's Guide for Apple iOS (Version 81); 2014:Retrieved from <http://g2npublishing.com/mpn/>.
137. Vannucchi AM, Guglielmelli P, Rotunno G, et al. Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project.
138. Bartalucci N, Guglielmelli P, Vannucchi AM. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. *Clinical Lymphoma, Myeloma & Leukemia*. 2013;13(S2):S307-309.
139. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. *N Engl J Med*. 2013;368:22-33.
140. Bogani C, Bartalucci N, Martinelli S, et al. mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms. *PLoS ONE*. 2013;8(1):e54826.
141. Vannucchi AM, Guglielmelli P, Pieri L, Susini MC. Sindromi mieloproliferative PH-. *Seminari di Ematologia Oncologica*. 2013;3:33-50.
142. Finazzi G, Vannucchi AM, Martinelli V, et al. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. *Brit J Haematol*. 2013;161(5):688-694.
143. Vannucchi AM, Guglielmelli P. JAK2 Mutation-Related Disease and Thrombosis. *Semin Thromb Hemost*. 2013;39(5):496-506.
144. Marchioli R, Vannucchi AM, Barbui T. Treatment Target in Polycythemia Vera. *N Engl J Med*. 2013;368(16):1554-1557.
145. Rosti V, Villani L, Riboni R, et al. Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation.
146. Pieri L, Loiacono I, Vannucchi AM. The burden of symptoms in myelofibrosis: From patient-reported outcomes to health economics. *Leukemia Research*. 2013;37(8):855-856.
147. Barbui T, Carobbio A, Finazzi G, et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis.
148. Poletto V, Villani L, Catarsi P, et al. No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis.
149. Guglielmelli P, Vannucchi AM. Struggling with myelofibrosis-associated anemia. *Leukemia Research*. 2013;37:1429-1431.
150. Spolverini A, Pieri L, Guglielmelli P, et al. Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis.
151. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.
152. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.
153. Jovanovic JV, Ivey A, Vannucchi AM, et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-

associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.

154. Klampfl T, Milosevic JD, Puda A, et al. Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. *PLoS ONE*. 2013;8(10):e77819.
155. Rumi E, Pietra D, Guglielmelli P, et al. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms.
156. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. *New Engl J Med*. 2013;369(25):2391-2405.
157. Cervantes F, Vannucchi AM, Kiladjan J-J, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
158. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis.
159. Bartalucci N, Tozzi L, Bogani C, et al. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. *Journal of Cellular and Molecular Medicine*. 2013;17(11):1385-1396.
160. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.
161. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.
162. Harrison CN, Cortes JE, Cervantes F, et al. Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF).
163. Schaap NP, Zweegman S, Jourdan E, et al. Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a P.... Vol. 122; 2013.
164. Vannucchi AM, Hagop K, Kiladjan J-J, et al. A Pooled Overall Survival Analysis of The COMFORT Studies: 2 Randomized Phase 3 Trials of Ruxolitinib For The Treatment of Myelofibrosis.
165. Puda A, Milosevic JD, Berg T, et al. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. *American Journal of Hematology*. 2012;87(3):245-250.
166. Villani L, Bergamaschi G, Primignani M, et al. JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms. *Leukemia Research*. 2012;36(1):e7-e9.
167. Carobbio A, Finazzi G, Thiele J, et al. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. *Am JHematol*. 2012;Oct 31. doi: 10.1002/ajh.22241.
168. Gale RP, Barosi G, Barbui T, et al. RBC-transfusion guidelines update. *Leuk Res*. 2012;36(5):659-660.

169. Barbui T, Thiele J, Passamonti F, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.
170. Bortoluzzi S, Bisognin A, Biasiolo M, et al. Characterization and discovery of novel miRNAs and moRNAs in JAK2V617F-mutated SET2 cells.
171. Buxhofer-Ausch V, Gisslinger H, Thiele J, et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. *Am J Hematol.* 2012;87(7):669-672.
172. Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph<sup>-</sup> negative MPN. *Am J Hematol.* 2012;87(5):552-554.
173. Abdel-Wahab O, Pardanani A, Bernard OA, et al. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposium. *American Journal of Hematology.* 2012;87(5):562-568.
174. Vannucchi AM, Pieri L, Susini MC, Guglielmelli P. BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques. *Future Oncology.* 2012;8(5):1-19.
175. Tefferi A, Pardanani A, Gangat N, et al. Leukemia risk models in primary myelofibrosis: an International Working Group study.
176. Barbui T, Thiele J, Carobbio A, et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early /prefibrotic primary myelofibrosis.
177. Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT.
178. Vannucchi AM, Pieri L, Antonioli E, Guglielmelli P. Targeted therapy in Philadelphia chromosome-negative chronic myeloproliferative neoplasms. *CML- Leukemia & Lymphoma.* 2012;20(1):1-18.
179. Milosevic JD, Puda A, Malcovati L, et al. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. *American Journal of Hematology.* 2012;87:1010-1016.
180. Cervantes F, Dupriez B, Passamonti F, et al. Improving Survival Trends In Primary Myelofibrosis: An International Study. *Journal of Clinical Oncology.* 2012;30(24):2981-2987.
181. Godfrey AL, Chen E, Pagano F, et al. JAK2V617F-homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.
182. Harrison C, Vannucchi AM. Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. *Therapeutic Advances in Hematology.* 2012;3(6):341-354.
183. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. *J Clin Oncol.* 2012;30(36):4098-40103.
184. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. *N Engl J Med.* 2012;366(9):787-798.
185. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis).

186. Cervantes F, Kiladjan J-J, Niederwieser D, et al. Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF). *ASH Annual Meeting Abstracts*. 2012;120(21):801-.
187. Vannucchi AM, Passamonti F, Al-Ali HK, et al. Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT). *ASH Annual Meeting Abstracts*. 2012;120(21):802-.
188. Harrison CN, Vannucchi AM. Closing the gap: genetic landscape of MPN.
189. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Myeloproliferative neoplasms: Morphology and clinical practice. *Am J Hematol*. 2015 Dec 30. doi:10.1002/ajh.24288. [Epub ahead of print]
190. Godfrey AL, Chen E, Massie CE, Silber Y, Pagano F, Bellosillo B, Guglielmelli P, Harrison CN, Reilly JT, Stegelmann F, Bijou F, Lippert E, Boiron JM, Döhner K, Vannucchi AM, Besses C, Green AR. STAT1 activation in association with JAK2 exon 12 mutations. *Haematologica*. 2016 Jan;101(1):e15-9. doi: 10.3324/haematol.2015.128546. Epub 2015 Dec 3.
191. Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. *Blood Cancer J*. 2015 Nov 27;5:e369. doi: 10.1038/bcj.2015.94.
192. Mesa R, Verstovsek S, Kiladjan JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Zhen H, Jones MM, Parasuraman S, Li J, Côté I, Habr D, Vannucchi AM. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. *Eur J Haematol*. 2015 Nov 26. doi: 10.1111/ejh.12707. [Epub ahead of print]
193. Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjan JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, Te Boekhorst PA, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. *J Clin Oncol*. 2016 Jan 10;34(2):151-9. doi: 10.1200/JCO.2015.62.9337. Epub 2015 Nov 23.
194. Salati S, Zini R, Nuzzo S, Guglielmelli P, Pennucci V, Prudente Z, Ruberti S, Rontautoli S, Norfo R, Bianchi E, Bogani C, Rotunno G, Fanelli T, Mannarelli C, Rosti V, Salmoiraghi S, Pietra D, Ferrari S, Barosi G, Rambaldi A, Cazzola M, Biccato S, Tagliafico E, Vannucchi AM, Manfredini R; AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative) investigators. Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis. *Int J Cancer*. 2016 Apr 1;138(7):1657-69. doi: 10.1002/ijc.29920. Epub 2015 Nov 25.
195. Martinaud C, Desterke C, Konopacki J, Vannucchi AM, Pieri L, Guglielmelli P, Dupriez B, Ianotto JC, Boutin L, Lataillade JJ, Le Bousse-Kerdilès MC. Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis. *Genom Data*. 2015 Apr 29;5:1-2. doi: 10.1016/j.gdata.2015.04.017. eCollection 2015 Sep.

196. Guglielmelli P, Bisognin A, Saccoman C, Mannarelli C, Coppe A, Vannucchi AM, Bortoluzzi S. Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells. *PLoS One*. 2015 Oct 15;10(10):e0140445. doi: 10.1371/journal.pone.0140445. eCollection 2015.
197. Guglielmelli P, Rotunno G, Pacilli A, Vannucchi AM. What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice? *Curr Hematol Malig Rep*. 2015 Dec;10(4):380-7. doi: 10.1007/s11899-015-0285-y.
198. Martinaud C, Desterke C, Konopacki J, Pieri L, Torossian F, Golub R, Schmutz S, Anginot A, Guerton B, Rochet N, Albanese P, Henault E, Pierre-Louis O, Souraud JB, de Revel T, Dupriez B, Ianotto JC, Bourgeade MF, Vannucchi AM, Lataillade JJ, Le Bousse-Kerdilès MC. Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis. *Cancer Res*. 2015 Nov 15;75(22):4753-65. doi: 10.1158/0008-5472.CAN-14-3696. Epub 2015 Sep 24.
199. Guglielmelli P, Rotunno G, Bogani C, Mannarelli C, Giunti L, Provenzano A, Giglio S, Squires M, Stalbovskaia V, Gopalakrishna P, Vannucchi AM; COMFORT-II Investigators. Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis. *Br J Haematol*. 2015 Aug 25. doi: 10.1111/bjh.13644. [Epub ahead of print]
200. Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kröger N, Thiele J, Buske C; ESMO Guidelines Committee. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015 Sep;26 Suppl 5:v85-99. doi: 10.1093/annonc/mdv203. Epub 2015 Aug 4.
201. Desterke C, Martinaud C, Guerton B, Pieri L, Bogani C, Clay D, Torossian F, Lataillade JJ, Hasselbach HC, Gisslinger H, Demory JL, Dupriez B, Boucheix C, Rubinstein E, Amsellem S, Vannucchi AM, Le Bousse-Kerdilès MC. Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.
202. Vannucchi AM, Kiladjian JJ, Grieshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. *N Engl J Med*. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002.
203. Barbui T, Thiele J, Carobbio A, Vannucchi AM, Tefferi A. The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinicomorphological diagnosis.
204. Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Pacilli A, Vannucchi AM, Passamonti F. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. *Am J Hematol*. 2014 Aug;89(8):E121-4. doi: 10.1002/ajh.23743. Epub 2014 May 16.

205. Barbui T, Thiele J, Carobbio A, Guglielmelli P, Rambaldi A, Vannucchi AM, Tefferi A. Discriminating between essential thrombocythemia and massive polycythemia vera in JAK2 mutated patients. *Am J Hematol*. 2014 Jun;89(6):588-90. doi: 10.1002/ajh.23694. Epub 2014 Mar 3.
206. Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I, Tenedini E, Pieri L, Paoli C, Mannarelli C, Fjerza R, Rumi E, Stalbovskaya V, Squires M, Cazzola M, Manfredini R, Harrison C, Tagliafico E, Vannucchi AM; COMFORT-II Investigators; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.
207. Bartalucci N, Bogani C, Vannucchi AM. Preclinical models for drug selection in myeloproliferative neoplasms. *Curr Hematol Malig Rep*. 2013 Dec;8(4):317-24. doi: 10.1007/s11899-013-0182-1. Review.
208. Bivanco-Lima D, Souza Santos Id, Vannucchi AM, Almeida Ribeiro MC. Cardiovascular risk in individuals with depression. *Rev Assoc Med Bras*. 2013 May-Jun;59(3):298-304. doi: 10.1016/j.ramb.2012.12.006. Epub 2013 May 16. Review.
209. Susini MC, Guglielmelli P, Spolverini A, Biamonte F, Mannarelli C, Barosi G, Zoi K, Reiter A, Duncombe A, Cervantes F, Cazzola M, Cross N, Vannucchi AM; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators. The ERCC2 Gln/Gln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis. *Br J Haematol*. 2013 Aug;162(3):424-7. doi: 10.1111/bjh.12376. Epub 2013 May 14.
210. Harrison CN, Mesa RA, Kiladjan JJ, Al-Ali HK, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-Merriman C, Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. *Br J Haematol*. 2013 Jul;162(2):229-39. doi: 10.1111/bjh.12375. Epub 2013 May 14.
211. Godfrey AL, Chen E, Pagano F, Ortmann CA, Silber Y, Bellosillo B, Guglielmelli P, Harrison CN, Reilly JT, Stegelmann F, Bijou F, Lippert E, McMullin MF, Boiron JM, Döhner K, Vannucchi AM, Besses C, Campbell PJ, Green AR. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.
212. Susini MC, Masala G, Antonioli E, Pieri L, Guglielmelli P, Palli D, Bosi A, Vannucchi AM. Risk of second cancers in chronic myeloproliferative neoplasms. *Blood*. 2012 Apr 19;119(16):3861-2; author reply 3862-3. doi: 10.1182/blood-2011-12-401455.
213. Vannucchi AM. Management of myelofibrosis. *Hematology Am Soc Hematol Educ Program*. 2011;2011:222-30. doi: 10.1182/asheducation-2011.1.222. Review.
214. Vannucchi AM, Biamonte F. Epigenetics and mutations in chronic myeloproliferative neoplasms.
215. Pieri L, Spolverini A, Scappini B, Occhini U, Birtolo S, Bosi A, Albano F, Fava C, Vannucchi AM. Concomitant occurrence of BCR-ABL and JAK2V617F mutation. *Blood*. 2011 Sep 22;118(12):3445-6. doi: 10.1182/blood-2011-07-365007.
216. Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.

217. Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, Fanelli T, Ernst T, Winkelmann N, Jones AV, Zoi K, Reiter A, Duncombe A, Villani L, Bosi A, Barosi G, Cross NC, Vannucchi AM. EZH2 mutational status predicts poor survival in myelofibrosis. *Blood*. 2011 Nov 10;118(19):5227-34. doi: 10.1182/blood-2011-06-363424. Epub 2011 Sep 14.
218. Gugliotta L, Tieghi A, Tortorella G, Scalzulli PR, Ciancia R, Lunghi M, Cacciola E, Cacciola R, Candoni A, Crugnola M, Codeluppi K, Usala E, Specchia G, Martinelli V, Palmieri F, Pierri I, Liberati AM, Iurlo A, Grossi A, Vannucchi AM, Vianelli N, Mazzucconi MG. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. *Leuk Res*. 2011 Dec;35(12):1557-63. doi: 10.1016/j.leukres.2011.06.030. Epub 2011 Jul 20.
219. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Müllauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. *J Clin Oncol*. 2011 Aug 10;29(23):3179-84. doi: 10.1200/JCO.2010.34.5298. Epub 2011 Jul 11.
220. Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, Biamonte F, Bartalucci N, Gattoni E, Lupo ML, Finazzi G, Pancrazzi A, Antonioli E, Susini MC, Pieri L, Malevolti E, Usala E, Occhini U, Grossi A, Caglio S, Paratore S, Bosi A, Barbui T, Vannucchi AM; AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
221. Pardananani A, Guglielmelli P, Lasho TL, Pancrazzi A, Finke CM, Vannucchi AM, Tefferi A. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.
222. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.
223. Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagicnski K, Olcaydu D, Passamonti F, Rumi E, Pietra D, Jäger R, Pieri L, Guglielmelli P, Iacobucci I, Martinelli G, Cazzola M, Vannucchi AM, Gisslinger H, Kralovics R. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. *Blood*. 2011 Jul 7;118(1):167-76. doi: 10.1182/blood-2011-01-331678. Epub 2011 Apr 29.
224. Guglielmelli P, Tozzi L, Bogani C, Iacobucci I, Ponziani V, Martinelli G, Bosi A, Vannucchi AM; AGIMM (AIRC-Gruppo Italiano Malattie Mieloproliferative) Investigators. Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera.
225. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. *Blood*. 2011 Jun 2;117(22):5857-9. doi: 10.1182/blood-2011-02-339002. Epub 2011 Apr 13.
226. Desterke C, Bilhou-Nabéra C, Guerton B, Martinaud C, Tonetti C, Clay D, Guglielmelli P, Vannucchi A, Bordessoule D, Hasselbalch H, Dupriez B, Benzoubir N, Bourgeade MF, Pierre-Louis

- O, Lazar V, Vainchenker W, Bennaceur-Griscelli A, Gisslinger H, Giraudier S, Le Bousse-Kerdilès MC; French Intergroup of Myeloproliferative Disorders,; French INSERM; European EUMNET Networks on Myelofibrosis. FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis. *Cancer Res.* 2011 Apr 15;71(8):2901-15. doi: 10.1158/0008-5472.CAN-10-1731. Epub 2011 Apr 12. Erratum in: *Cancer Res.* 2011 Jun 1;71(11):4049-50.
227. Barosi G, Rosti V, Vannucchi AM. Therapeutic approaches in myelofibrosis. *Expert Opin Pharmacother.* 2011 Jul;12(10):1597-611. doi: 10.1517/14656566.2011.568939. Epub 2011 Apr 4. Review.
228. Varricchio L, Masselli E, Alfani E, Battistini A, Migliaccio G, Vannucchi AM, Zhang W, Rondelli D, Godbold J, Ghinassi B, Whitsett C, Hoffman R, Migliaccio AR. The dominant negative  $\beta$  isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients.
229. Vannucchi AM, Pieri L, Guglielmelli P. JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. *Ther Adv Hematol.* 2011 Feb;2(1):21-32. doi: 10.1177/2040620710394474.
230. Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, Kiladjian JJ, McMullin MF, Ruggeri M, Besses C, Vannucchi AM, Lippert E, Gisslinger H, Rumi E, Lehmann T, Ortmann CA, Pietra D, Pascutto C, Haferlach T, Cazzola M. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. *Blood.* 2011 Mar 10;117(10):2813-6. doi: 10.1182/blood-2010-11-316810. Epub 2011 Jan 11.
231. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. *J Clin Oncol.* 2011 Feb 20;29(6):761-70. doi: 10.1200/JCO.2010.31.8436. Epub 2011 Jan 4.